NervGen Pharma Corp. (TSXV: NGEN)
Canada
· Delayed Price · Currency is CAD | Market Cap | 201.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.01M |
| Shares Out | 70.31M |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,800 |
| Average Volume | 36,975 |
| Open | 2.830 |
| Previous Close | 2.820 |
| Day's Range | 2.820 - 2.900 |
| 52-Week Range | 1.650 - 3.980 |
| Beta | 1.39 |
| RSI | 45.78 |
| Earnings Date | Feb 27, 2025 |
About NervGen Pharma
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer’s disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cor... [Read more]
Financial Performance
Financial StatementsNews
NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Vancouver, Canada--(Newsfile Corp. - January 29, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today...
NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration
NervGen completed enrollment for its phase 2 trial in spinal cord injury, setting the countdown for topline results in Q2, 2024. The research suggests that the company may have a solution for nervous ...
NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
Topline data from the chronic cohort is expected in Q2 2025 Institutional Review Board (IRB) protocol amendment changes approved, and screening has been initiated for subacute cohort This news release...
Undercovered Dozen: OppFi, PowerFleet, Eletrobras, American Battery +
Discover twelve undercovered stocks with potential like American Battery Technology, Quantum Corporation, and NervGen Pharma Corp.
NervGen: Data For Spinal Cord Injury Treatment Candidate Likely For Mid-2025
NervGen's NVG-291 shows promising preclinical results in spinal cord injury, with significant improvements in motor function and nerve regeneration, positioning it as a potential breakthrough in nervo...
NervGen Announces "At-The-Market" Equity Program
Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to develop...
NervGen Pharma GAAP EPS of -$0.07
NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates
Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury (SCI) is approaching completion NVG-300 preclinical test-of-concept studies ...
NervGen Pharma to Present at the Stifel 2024 Healthcare Conference
Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeut...
NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
Target enrollment in the chronic cohort close to completion Vancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biot...
NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury
Vancouver, British Columbia--(Newsfile Corp. - September 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for...
NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting
Vancouver, British Columbia--(Newsfile Corp. - September 16, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for...
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for th...
NervGen Pharma reports Q2 results
NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates
Targeting to complete enrollment in the Phase 1b/2a chronic cohort in Q3 2024 Protocol being amended to enhance enrollment and lessen burden on participants in the subacute cohort NVG-300 advanced int...
NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference
Vancouver, British Columbia--(Newsfile Corp. - August 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the...
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - August 2, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) a clinical stage biotech company dedicated to developing innovative solutions for the ...
NervGen Pharma Appoints Neil Klompas to Board of Directors
Seasoned pharmaceutical executive with extensive experience in high-growth life sciences companies joins NervGen Leadership appointment supports the company's mission to advance NVG-291 after the comp...
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage
New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen...
NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the ...
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
All resolutions submitted for approval were passed by shareholders Glenn Ives appointed as Chair of the Board John Ruffolo appointed as Chair of the Audit Committee Vancouver, British Columbia--(Newsf...
NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the t...
NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates
Target for completing enrollment of the chronic cohort in the Phase 1b/2a clinical trial moved to Q3 2024 Subacute cohort protocol being amended to enhance feasibility and lessen burden on participant...
NervGen Files Management Information Circular and Announces Board of Directors Transition
Bill Radvak to transition to Board Advisor following decision to not stand for re-election to NervGen's Board of Directors Annual General Meeting of Shareholders to be held on June 4, 2024 Vancouver, ...
NervGen Engages Russo Partners LLC to Provide Public Relations Services
Vancouver, British Columbia--(Newsfile Corp. - April 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing...